Oncology Xagena

Xagena Mappa
Xagena Newsletter

Search results for "Votrient"

A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer.At the annual meeting of the American Society of Clinical O ...

Pazopanib ( Votrient ) and Sunitinib ( Sutent ) provided a progression-free survival benefit, as compared with placebo or Interferon, in previous phase 3 studies involving patients with metastatic ren ...

Antiangiogenic agents Sunitinib ( Sutent ) and Pazopanib ( Votrient ) are SOC ( standard of care ) for metastatic renal cell carcinoma ( mRCC ), but new therapies are needed as patients advance throug ...